MA5-23903

antibody from Invitrogen Antibodies

Targeting: IFNL1 IL-29, IL29

ELISA (Recommended by provider)

Blocking/Neutralizing (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA5-23903

Provider

Invitrogen Antibodies

Product name

IL-29 Monoclonal Antibody (247801)

Antibody type

Monoclonal

Antigen

Recombinant full-length protein

Description

In sandwich ELISAs, 100% cross-reactivity with recombinant human (rh) IL-28B/IFN-lambda 3 and 20% with rhIL-28A is observed. No cross-reactivity or interference was observed with rhIFN-alpha A, rhIFN-alpha B2, rhIFN-alpha G, rhIFN-alpha I, or rhIFN- beta 1A. Reconstitute at 0.5 mg/mL in sterile PBS. Endoxin level is

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

247801

Vial size

100 µg

Concentration

0.5 mg/mL

Storage

-20° C, Avoid Freeze/Thaw Cycles

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Neutralization antibody testing demonstrates the specificity of an antibody through a correlation between antibody binding and the activity of the target. Neutralization of IL-29 is shown by decrease in RFU (measure of cytopathy) with increasing concentrations of IL-29 monoclonal antibody (MA5-23791).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Neutralization of IL-29 in HepG2 human hepatocellular carcinoma cell line. Samples were incubated in IL-29 monoclonal antibody (Product # MA5-23903). Recombinant Human IL‚29/IFN‚λ1 reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Human IL‚29/IFN‚λ1 (40 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anri-Human IL‚29/IFN‚λ1 Monoclonal Antibody. The ND50 is typically 1-4 µg/mL.